Mylan To Pay $4 Bil. For King Ahead Of Launch Of Beta Blocker Nebivolol

The company cites King’s 1,200-person sales force as one reason behind the acquisition. King’s cardiovascular marketing experience with the ACE inhibitor Altace will be beneficial as Mylan anticipates approval for its beta blocker nebivolol.